合盛硅業(603260.SH):2022年度擬開展外匯衍生品交易業務 規模總額不超2億元
格隆匯9月21日丨合盛硅業(603260.SH)公佈,公司於2022年9月21日召開第三屆董事會第十四次會議,審議通過了《關於2022年度開展外匯衍生品交易業務的議案》,同意公司及子公司開展外匯衍生品交易業務。公司及子公司預計2022年度擬開展的外匯衍生品交易業務規模總額不超過2億元人民幣(其他幣種按當期匯率折算成人民幣彙總,在任一時間點衍生品交易業務規模不超過2億元人民幣,額度範圍內資金可循環使用)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.